Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles

Pfizer and BioNTech halted recruitment for a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50-64 because enrollment was too low to generate the needed data. The pause is a program-level setback that may delay data readouts and regulatory submissions for the update and could weigh on near-term vaccine revenue and investor sentiment. There is no indication of safety or efficacy failure, so impacts are likely limited to timing and guidance uncertainty rather than a product discontinuation.

Analysis

Pfizer and BioNTech halted recruitment for a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50-64 because enrollment was too low to generate the needed data. The pause is a program-level setback that may delay data readouts and regulatory submissions for the update and could weigh on near-term vaccine revenue and investor sentiment. There is no indication of safety or efficacy failure, so impacts are likely limited to timing and guidance uncertainty rather than a product discontinuation.